Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Phase 2

Active, not recruiting

Conditions: Malignant Neoplasm

Interventions: Biological: aldesleukin
Drug: fludarabine phosphate
Drug: cyclophosphamide
Other: laboratory biomarker analysis
Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Biological: dendritic cell vaccine therapy
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography

First Posted Date: 2012-10-02

Last Posted Date: 2024-11-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT01697527

Locations: 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IV Non-small Cell Lung Cancer

Interventions: Drug: exemestane
Drug: pemetrexed disodium
Drug: carboplatin
Other: laboratory biomarker analysis
Other: pharmacological study
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2012-08-14

Last Posted Date: 2019-05-07

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT01664754

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Phase 2

Completed

Conditions: Adult Diffuse Astrocytoma
Recurrent Adult Brain Tumor
Adult Oligoastrocytoma
Adult Mixed Glioma
Adult Oligodendroglioma

Interventions: Biological: tumor lysate-pulsed autologous dendritic cell vaccine
Other: laboratory biomarker analysis

First Posted Date: 2012-07-09

Last Posted Date: 2020-11-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT01635283

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Survivorship Care Plan

First Posted Date: 2012-06-25

Last Posted Date: 2016-08-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 500

Registration Number: NCT01627366

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Localized Unresectable Adult Primary Liver Cancer
Localized Resectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: sorafenib tosylate
Other: placebo
Other: laboratory biomarker analysis

First Posted Date: 2012-06-20

Last Posted Date: 2023-12-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT01624285

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

and more 18 locations

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Newly Diagnosed Glioblastoma Multiforme

Interventions: Other: Lapatinib/Temozolomide/radiation

First Posted Date: 2012-05-04

Last Posted Date: 2024-05-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT01591577

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors

Phase 2

Completed

Conditions: Younger Breast Cancer Survivors

Interventions: Behavioral: Mindful Awareness practices (MAPs)

First Posted Date: 2012-03-20

Last Posted Date: 2015-04-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 71

Registration Number: NCT01558258

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Improving Cognition with group intervention

First Posted Date: 2012-02-29

Last Posted Date: 2015-04-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 48

Registration Number: NCT01540955

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Phase 2

Completed

Conditions: Ovarian Epithelial Carcinoma

Interventions: Drug: PD0332991

First Posted Date: 2012-02-22

Last Posted Date: 2020-06-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT01536743

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

Not Applicable

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Apricoxib

First Posted Date: 2012-02-14

Last Posted Date: 2020-09-22

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT01532362

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy